Tandem Multi-modal Plate Readers for a High Throughput Screening platform

项目概要： 斯克里普斯研究分子筛选中心（SRMSC）正在申请资金，用于购买 两个酶标仪作为其目前的uHTS Perkin Elmer Viewlux的替代品， 生命的终结ViewLux一直是高速微孔板成像的黄金标准;非常适合 用于同时进行板-孔成像分析，其中需要速度、可靠性和高质量数据。 我们HTS筛查平台上的集成Viewlux阅读器非常适合我们的需求， 在2005年的第一次分期付款。然而，经过15年的服务，可靠性已成为一个关键问题 Perkin Elmer的停产（2017年）和服务支持加剧了 停止生产所有零件/组件。到目前为止，还没有一个当前的读者， 市场，等于Viewlux的速度，这是特别有问题的，就以往任何时候 增加了执行弱光发光和BRET读出的需要。毫不奇怪，许多 全面的HTS筛查中心（包括制药和学术）现在必须依赖多个阅读器 满足HTS自动化吞吐量需求，同时保持高质量和可靠的数据。高 探针筛选技术已成为探针开发和药物筛选中不可缺少的工具 发现和斯克里普斯研究分子筛选中心（SRMSC）一直处于前列 在斯克里普斯和其他学术机构为NIH研究人员服务。自成立以来， 2005年，我们筛选了300多个目标，为我们的 Scripps和其他机构的合作者。超过122篇科学论文， 演示文稿展示了我们制作优秀的研究驱动数据的能力。我们的筛选结果 已经导致了超过77种生物活性分子探针的开发，作为新的药物靶点， 生物医学研究已成功地作为IND进行临床试验测试，并最终 NDA/FDA药物。串联多模式读板器将取代老化的ViewLux;允许 SRMSC履行其目前的HTS筛查义务，并继续为NIH社区服务， 凭借其全面的HTS药物发现能力。

PROJECT SUMMARY: The Scripps Research Molecular Screening Center (SRMSC) is requesting funds for the purchase of two microplate readers as a replacement for its current uHTS Perkin Elmer Viewlux which has reached end of life. The ViewLux has been the gold standard for high-speed microplate imaging; ideally suited for simultaneous plate-well imaging analysis where speed, reliability and high quality data is required. The integrated Viewlux reader on our HTS screening platform has served our needs admirably since its initial installment in 2005. However, after ~15-years of service, reliability has become a critical issue compounded by Perkin Elmer’s end of production (2017) and service support exacerbated by the discontinued manufacture of all parts/components. As of date, there is not a current reader on the market that equals the speed of the Viewlux, which is especially problematic with respect to ever increasing need to perform low light luminescence and BRET readouts. Not surprisingly, many comprehensive HTS screening centers (both Pharma & academic) must now rely on multiple readers to meet HTS automation throughput needs while maintaining high quality and reliable data. High Throughput Screening (HTS) has become an indispensable tool for probe development and drug discovery and the Scripps Research Molecular Screening Center (SRMSC) has been in the forefront in serving NIH investigators at Scripps and other academic institutes. Since establishing operations in 2005, we have screened over 300 targets to generate more than 100 million data points for our collaborators at Scripps and at other institutions. Over 122 scientific papers and numerous presentations demonstrate our ability to produce excellent research-driven data. Our screening results have led to the development of over 77 bioactive molecular probes as novel drug targets for biomedical studies that have successfully advanced as INDs for clinical trial testing and eventually NDA/FDA drugs. The tandem multi-modal plate readers will replace the aged ViewLux; allowing SRMSC to fulfill its current HTS screening obligations and continue to serve the NIH community at large with its comprehensive HTS drug discovery capabilities.